David Chu

David Chu

Company: Arcutis Biotherapeutics

Job title: MD, PhD, Vice President, Clinical Development


Directed Drug Delivery to the Skin: Topical Roflumilast as a Model for Development of Treatment for Immune-Mediated Skin Disease | VIRTUAL 2:00 pm

Considering vehicle formulation for optimized drug delivery Developing topical treatment designed for widespread use on the skin Selecting an MOA suitable for treatment of multiple immune-mediated skin diseasesRead more

day: Day 2 PM - Track B

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.